Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.57 |
| ▸ | ITGAV | P06756 | 18/20 | 0.57 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 9/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.48 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.48 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23455311 | 0.88 | ITGB1 (0.61) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL23489508 | 0.88 | ITGB1 (0.61) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL23518372 | 0.88 | ITGB3 (0.56) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL23489345 | 0.86 | ITGB1 (0.55) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL23455402 | 0.86 | ITGB1 (0.55) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL23518208 | 0.85 | ITGB1 (0.64) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL23518473 | 0.85 | ITGB1 (0.49) | ITGB3ITGAVITGB6ITGB1ITGB5 | |
| SCHEMBL23518379 | 0.84 | ITGB1 (0.46) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL23489521 | 0.82 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL30073964 | 0.82 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2021119199-A1 | ALPHA-5 BETA-1 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-17 | — | — | WO | disclosed |
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171455-A1 | ALPHA-5 BETA-1 INHIBITORS | SCN5A, PSMA5, API5 | ITGB3 957/4885ITGAV 1756/4885ITGB6 1013/4885 |
| US-11530180-B2 | Alpha-5 beta-1 inhibitors | SCN5A, PSMA5, API5 | ITGB3 957/4885ITGAV 1756/4885ITGB6 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.